Prothrombin fragment 1+2 (F1+2): a marker of clotting activity explained

Blood clotting runs as a chain reaction. Near the end of the chain, an inactive protein called prothrombin is cut by a complex of clotting factors, and the cut produces thrombin, the enzyme that turns fibrinogen into the fibrin mesh of a clot. A laboratory test directory explains that fragment 1+2 is generated as a by-product of this in vivo cleavage of prothrombin into thrombin by membrane-bound prothrombinase.

Thrombin itself is short-lived and quickly mopped up by inhibitors, so it is hard to measure directly. A related research article makes the same point: F1+2 is formed as a by-product during conversion of prothrombin to thrombin, so coagulation status can be judged by measuring F1+2 in plasma. In effect, it counts the number of thrombin molecules the body has made.

The laboratory directory adds that F1+2 has a biological half-life of 90 minutes, so it persists in blood for several hours after it forms. That relatively long presence is why it is considered more reliable for measuring ongoing coagulation than markers that disappear within minutes.

The test is run on plasma, the liquid part of blood, collected into a tube containing sodium citrate (a blue-top tube). The laboratory directory describes the method as a sandwich enzyme immunoassay: F1+2 in the sample binds to antibodies fixed to a microtitre plate, an enzyme-linked second antibody is added, and the colour that develops is proportional to the amount of F1+2.

Collection technique matters. The directory warns that improper collection, or insufficient mixing of blood with anticoagulant in the tube, can lead to falsely elevated F1+2 values, and that people who have been given monoclonal mouse antibodies, for treatment or imaging, may get erroneous results. The sample is mixed by gentle inversion, spun twice in a centrifuge and frozen. Because of this handling, the test is usually run in batches at a reference laboratory, and the same directory gives a usual turnaround of 5 to 9 days.

The directory is a United States laboratory's, so specimen volumes and turnaround at a UK laboratory may differ. A urine version has also been used in research, because the fragment is small enough to be excreted by the kidneys.

Because F1+2 reflects thrombin generation, anything that activates clotting can push it up. The laboratory directory lists increases in pregnancy and in women taking pills containing ethinylestradiol, and reports elevated levels in antiphospholipid syndrome, protein C deficiency, protein S deficiency, and in carriers of the prothrombin G20210A and factor V Leiden mutations who have no symptoms.

It also reports raised values in venous thromboembolism, acute coronary syndromes, stroke, atrial fibrillation, peripheral arterial disease, COVID-19 and a number of cancers. Anticoagulant medicines have been found to reduce F1+2 levels, which is consistent with their purpose of damping down thrombin production.

• Clotting disorders and inherited thrombophilias, including protein C or S deficiency.

• Pregnancy and oestrogen-containing contraception.

• Active blood clots, including deep vein thrombosis and pulmonary embolism.

• Arterial disease, such as acute coronary syndromes and stroke.

• Cancer and some infections.

• Lower values on anticoagulant treatment, and falsely high values from poor sample handling.

Several studies have tried to use F1+2 to anticipate venous thromboembolism. A Danish-led study measured urinary F1+2 in 142 patients who developed a clot after total knee replacement and 140 matched controls. Median urinary levels were significantly higher in the clot group on days 1, 3 and the day of venography, but the authors say the discriminatory efficacy of the test could not be evaluated, and most of the clots found were non-symptomatic deep vein thromboses detected on scanning.

A 2025 Chinese study of 137 patients with advanced cancer, 49 of whom had a venous thromboembolism, found that D-dimer and F1+2 were each independent risk factors after chemotherapy, and the authors concluded both were reliable indicators. That was a single-hospital study in which patients chose whether to receive preventive anticoagulation, so it cannot show cause and effect.

Taken together, these studies show that F1+2 tracks clotting activity in groups of patients. They do not show that an individual result should be used on its own to decide treatment. A study group average and a decision about one person are different things.

In routine NHS practice, suspected clots are assessed clinically and with imaging. The NHS says that if a doctor thinks you have deep vein thrombosis, you should be referred to hospital within 24 hours for an ultrasound scan, and that treatment is with blood-thinning medicines, usually for at least 3 months. The NHS page on pulmonary embolism describes hospital tests and anticoagulant injections followed by tablets. Neither mentions F1+2.

The test is therefore a specialist or research tool. A haematologist may use it in a complex case of unexplained clotting or suspected consumptive coagulopathy, but it is not a screening test, and a normal value does not rule out a clot. If you have been offered this test privately, ask which decision it is intended to guide, and whether the result would change treatment.

The NHS says that DVT is more likely in people over 60, those with overweight or obesity, smokers, people who have had DVT before, people taking HRT or the combined pill, those with cancer, heart failure or thrombophilia, and around hospital stays, surgery, long journeys and pregnancy. Those practical risk factors, rather than F1+2, are what clinicians weigh first.

Do not wait for a laboratory result if you have symptoms. The NHS says to ask for an urgent GP appointment or get help from NHS 111 if you think you have DVT, which can cause throbbing pain and swelling in one leg, usually the calf or thigh, with red, blue or darkened skin.

Call 999 or go to A&E if you have symptoms of DVT and also feel short of breath or have chest pain, because the clot may have travelled to the lungs. For suspected pulmonary embolism, the NHS lists sudden difficulty breathing, chest pain that is worse when you breathe in and coughing up blood. The NHS says not to drive yourself to A&E.